{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":6,"podcast":3,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05943106\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PATAPSCO","nct_id":"NCT05943106","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=patapsco-nct05943106. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"PATAPSCO","arms":[{"description":"Participants will receive Durvalumab for 13 cycles every 4 weeks (q4w) for a maximum 12 months. All participants will receive BCG (supplied by the site) intravesically, as induction weekly for 6 weeks. Patients will subsequently receive BCG for maintenance for 3 weekly doses at 3,6,12,18, and up to 24 months, at the physician's discretion.","label":"Durvalumab + BCG","type":"EXPERIMENTAL"}],"collaborators":["Parexel"],"completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"conditions":["Non-Muscle- Invasive Bladder Cancer"],"enrollment":{"count":100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"BIOLOGICAL"},{"name":"BCG","type":"BIOLOGICAL"}],"last_update":"2026-08-13","lead_sponsor":"AstraZeneca","official_title":"A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs)","timeFrame":"From the date of the first dose of study treatment (Day 1) until 6 months after the initiation of study treatment"}],"references":[],"start_date":{"date":"2023-08-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","url":"https://clinicaltrials.gov/study/NCT05943106"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/patapsco-nct05943106"}